Hypoxia-responsive drug–drug conjugated nanoparticles for breast cancer synergistic therapy
- 17 March 2016
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 6 (36) , 30268-30276
Abstract
(A) Chemical structure of IR–AZO–CA4 molecule and preparation of IR–AZO–CA4/CP NPs. (B) Schematic illustration of the hypoxia-responsive drug–drug conjugated NPs in hypoxic cells and normoxic cells.Keywords
This publication has 35 references indexed in Scilit:
- Effect of surface charge on the colloidal stability and in vitro uptake of carboxymethyl dextran-coated iron oxide nanoparticlesJournal of Nanoparticle Research, 2013
- Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer CellsCell, 2011
- Normal and neoplastic nonstem cells can spontaneously convert to a stem-like stateProceedings of the National Academy of Sciences, 2011
- Nanoparticle mediated targeting of VEGFR and cancer stem cells for cancer therapyVascular Cell, 2011
- Breast Cancer Cell Lines Contain Functional Cancer Stem Cells with Metastatic Capacity and a Distinct Molecular SignatureCancer Research, 2009
- Breast cancer stem cells: implications for therapy of breast cancerBreast Cancer Research, 2008
- Use of BRCA1 protein:protein interactions to classify cancer riskBreast Cancer Research, 2008
- HEDGEHOG-GLI1 Signaling Regulates Human Glioma Growth, Cancer Stem Cell Self-Renewal, and TumorigenicityCurrent Biology, 2007
- Beyond tumorigenesis: cancer stem cells in metastasisCell Research, 2006
- Hypoxia — a key regulatory factor in tumour growthNature Reviews Cancer, 2002